PCT experts Robert Shaw, VP, Commercial Development; Brian Hampson, VP Manufacturing Development & Engineering, and Candice Betz, Director of QA/QC, have recently co-authored an article in BioProcessing Journal, titled "The Race to Market: Regulation of Cell-Based Therapies and Considerations for Process Development". The article touches upon the state of regulation in the cell therapy industry in both the U.S. and abroad, and offers insights and recommendations for operating effectively within the applicable regulatory frameworks.
Click here to read the full article.
*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
